SCHEMBL3485348

SCHEMBL3485348

O=[N+]([O-])c1cc(C(F)(F)F)ccc1N1CCc2ccccc21

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.58
ALDH1A1 P00352 8/20 0.58
MAPK1 P28482 7/20 0.58
MEN1 O00255 5/20 0.58
KMT2A Q03164 5/20 0.58
GAA P10253 2/20 0.58
LMNA P02545 8/20 0.53
SMN1; SMN2 Q16637 4/20 0.53
L3MBTL1 Q9Y468 4/20 0.53
TDP1 Q9NUW8 2/20 0.50
HTT P42858 2/20 0.50
RECQL P46063 1/20 0.49
CYP1A2 P05177 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2D6 P10635 1/20 0.49
CYP2C9 P11712 1/20 0.49
CYP2C19 P33261 1/20 0.49
RAB9A P51151 1/20 0.48
NPSR1 Q6W5P4 1/20 0.47
KDM4E B2RXH2 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25027154 0.90 MAPT (0.50) MAPTALDH1A1MAPK1MEN1KMT2A
SCHEMBL31053815 0.90 MAPT (0.50) MAPTALDH1A1MAPK1MEN1KMT2A
SCHEMBL10620800 0.83 MAPT (0.64) MAPTALDH1A1MAPK1MEN1KMT2A
SCHEMBL3484761 0.81 MAPT (0.64) MAPTALDH1A1MAPK1MEN1KMT2A
SCHEMBL11464258 0.81 ALDH1A1 (0.61) MAPTALDH1A1MAPK1MEN1KMT2A
SCHEMBL10620880 0.81 MEN1 (0.65) MAPTALDH1A1MAPK1MEN1KMT2A
SCHEMBL10620782 0.81 MAPT (0.62) MAPTALDH1A1MAPK1MEN1KMT2A
SCHEMBL10625894 0.81 MAPK1 (0.62) MAPTALDH1A1MAPK1MEN1KMT2A
SCHEMBL3484758 0.79 MAPT (0.61) MAPTALDH1A1MAPK1MEN1KMT2A
SCHEMBL3485924 0.79 ALDH1A1 (0.54) MAPTALDH1A1MAPK1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4188488-A ALKYLIMIDAZOLYL SUBSTITUENTS GIVAUDAN CORPORATION (US) 1980-02-12 US claimed
EP-2666481-B9 Method of regulating phosphorylation of sr protein and antiviral agents comprising sr protein activity regulator as the active ingredient HAGIWARA MASATOSHI (JP) 2019-05-22 EP disclosed
EP-2666481-B1 Method of regulating phosphorylation of sr protein and antiviral agents comprising sr protein activity regulator as the active ingredient HAGIWARA MASATOSHI (JP) 2018-11-14 EP disclosed
EP-1712242-B1 METHOD OF REGULATING PHOSPHORYLATION OF SR PROTEIN AND ANTIVIRAL AGENTS COMPRISING SR PROTEIN ACTIVITY REGULATOR AS THE ACTIVE INGREDIENT HAGIWARA MASATOSHI (JP) 2018-05-30 EP disclosed
US-8816089-B2 Methods for controlling SR protein phosphorylation, and antiviral agents whose active ingredients comprise agents that control SR protein activity Hagiwara, Masatoshi (JP) 2014-08-26 US disclosed
US-8816089-B2 Methods for controlling SR protein phosphorylation, and antiviral agents whose active ingredients comprise agents that control SR protein activity Hagiwara, Masatoshi (JP) 2014-08-26 US disclosed
US-8816089-B2 Methods for controlling SR protein phosphorylation, and antiviral agents whose active ingredients comprise agents that control SR protein activity Hagiwara, Masatoshi (JP) 2014-08-26 US disclosed
CN-101837125-B Method of regulating phosphorylation of PTH protein and antiviral agents comprising SR protein activity regulator as the active ingredient HAGIWARA MASATOSHI 2014-02-26 CN disclosed
EP-2666481-A2 Method of regulating phosphorylation of sr protein and antiviral agents comprising sr protein activity regulator as the active ingredient HAGIWARA, Masatoshi (JP) 2013-11-27 EP disclosed
CN-1921885-B Use of an aniline derivative or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a viral infection in a patient HAGIWARA MASATOSHI 2013-06-12 CN disclosed
US-20100016359-A1 METHODS FOR CONTROLLING SR PROTEIN PHOSPHORYLATION, AND ANTIVIRAL AGENTS WHOSE ACTIVE INGREDIENTS COMPRISE AGENTS THAT CONTROL SR PROTEIN ACTIVITY MASATOSHI HAGIWARA 2010-01-21 US disclosed
US-7569536-B2 Broad spectrum antiviral including against SARS (severe acute respiratory syndrome), DNA viruses and herpes viruses; Ser-Arg (SR), SR proteins are RNA-binding proteins; compounds are SRPK inhibitors such as 1-piperidino-2-(pyridin-4-ylcarbonylamino)-4-trifluoromethylbenzene Hagiwara, Masatoshi (JP) 2009-08-04 US disclosed
US-7569536-B2 Broad spectrum antiviral including against SARS (severe acute respiratory syndrome), DNA viruses and herpes viruses; Ser-Arg (SR), SR proteins are RNA-binding proteins; compounds are SRPK inhibitors such as 1-piperidino-2-(pyridin-4-ylcarbonylamino)-4-trifluoromethylbenzene Hagiwara, Masatoshi (JP) 2009-08-04 US disclosed
US-7569536-B2 Broad spectrum antiviral including against SARS (severe acute respiratory syndrome), DNA viruses and herpes viruses; Ser-Arg (SR), SR proteins are RNA-binding proteins; compounds are SRPK inhibitors such as 1-piperidino-2-(pyridin-4-ylcarbonylamino)-4-trifluoromethylbenzene Hagiwara, Masatoshi (JP) 2009-08-04 US disclosed
US-20070135367-A1 Broad spectrum antiviral including against SARS (severe acute respiratory syndrome), DNA viruses and herpes viruses; Ser-Arg (SR), SR proteins are RNA-binding proteins; compounds are SRPK inhibitors such as 1-piperidino-2-(pyridin-4-ylcarbonylamino)-4-trifluoromethylbenzene HAGIWARA, MASATOSHI (JP) 2007-06-14 US disclosed
US-20070135367-A1 Broad spectrum antiviral including against SARS (severe acute respiratory syndrome), DNA viruses and herpes viruses; Ser-Arg (SR), SR proteins are RNA-binding proteins; compounds are SRPK inhibitors such as 1-piperidino-2-(pyridin-4-ylcarbonylamino)-4-trifluoromethylbenzene HAGIWARA, MASATOSHI (JP) 2007-06-14 US disclosed
US-20070135367-A1 Broad spectrum antiviral including against SARS (severe acute respiratory syndrome), DNA viruses and herpes viruses; Ser-Arg (SR), SR proteins are RNA-binding proteins; compounds are SRPK inhibitors such as 1-piperidino-2-(pyridin-4-ylcarbonylamino)-4-trifluoromethylbenzene HAGIWARA, MASATOSHI (JP) 2007-06-14 US disclosed
CN-1921885-A Method for controlling phosphorylation of SR protein and antiviral agent comprising SR protein activity controller as active ingredient HAGIWARA MASATOSHI (JP) 2007-02-28 CN disclosed
EP-1712242-A1 METHOD OF REGULATING PHOSPHORYLATION OF SR PROTEIN AND ANTIVIRAL AGENTS COMPRISING SR PROTEIN ACTIVITY REGULATOR AS THE ACTIVE INGREDIENT HAGIWARA, Masatoshi (JP) 2006-10-18 EP disclosed
US-4186199-A Indolo-,1,2-dihydroindolo-, and 1,2,6,7-tetrahydroindolo [1,7-ab][1,5] benzodiazepines AMERICAN HOECHST CORPORATION (US) 1980-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135367-A1 Broad spectrum antiviral including against SARS (severe acute respiratory syndrome), DNA viruses and herpes viruses; Ser-Arg (SR), SR proteins are RNA-binding proteins; compounds are SRPK inhibitors such as 1-piperidino-2-(pyridin-4-ylcarbonylamino)-4-trifluoromethylbenzene SRPK1, SARS1, SRPK3 MAPT 3497/4885ALDH1A1 4791/4885MAPK1 999/4885
US-20100016359-A1 METHODS FOR CONTROLLING SR PROTEIN PHOSPHORYLATION, AND ANTIVIRAL AGENTS WHOSE ACTIVE INGREDIENTS COMPRISE AGENTS THAT CONTROL SR PROTEIN ACTIVITY SRPK1, SRPK3, SRPK2 MAPT 3912/4885ALDH1A1 4854/4885MAPK1 617/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.